Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2023-12-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司十届一次监事会决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of a supervisory board resolution regarding the election of the chairman of the supervisory board. It includes details about the meeting, voting results, and a brief biography of the elected chairman. There are no financial statements, no quarterly or annual financial data, no audit information, and no mention of report publication. The content is about board/management changes, specifically the election of a supervisory board chairman, which falls under Board/Management Information (MANG). The document length is short and it is not a report or a report announcement, but a formal announcement of a management change.
2023-12-27 Chinese
上海市海华永泰（哈尔滨）律师事务所关于哈药集团股份有限公司2023年第一次临时股东大会之法律意见书
Regulatory Filings
2023-12-27 Chinese
哈药集团股份有限公司2023年第一次临时股东大会会议材料
AGM Information Classification · 100% confidence The document is titled as "2023年第一次临时股东大会会议材料" which translates to "2023 First Extraordinary General Meeting (EGM) Materials". It contains detailed meeting materials including agenda, proposals for amendments to company bylaws, election of board members, and voting procedures. The content is comprehensive and clearly intended for the shareholders' meeting itself, not just an announcement or summary. The document length is 15,000 characters, indicating it is a full set of meeting materials rather than a brief notice or announcement. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. There is no indication that this is an annual report, audit report, or other financial report. It is not a voting result announcement (DVA) because it contains the meeting materials, not just results. Therefore, the correct classification is AGM Information (AGM-R).
2023-12-18 Chinese
哈药集团股份有限公司董事会秘书工作制度（2023年12月）
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作制度' which translates to 'Board Secretary Work System'. It outlines the rules, responsibilities, appointment, and duties of the company's board secretary. It references relevant laws and regulations but does not contain financial data, earnings, or report disclosures. It is a governance-related document detailing internal rules and governance practices for the board secretary role. The document length is 2732 characters, which is relatively short and focused on governance policies rather than financial reporting or announcements. Therefore, the most appropriate classification is Governance Information (CGR).
2023-12-11 Chinese
哈药集团股份有限公司股东大会议事规则（2023年12月）
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting" of 哈药集团股份有限公司. It details the rules, procedures, rights, and responsibilities related to the conduct of shareholders' meetings, including the organization, notification, proposal submission, voting procedures, and legal compliance. It does not contain financial statements, audit opinions, or earnings data. It is a governance-related document outlining internal rules and governance practices for shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length is over 10,000 characters, indicating it is a full document, not a brief announcement or notice.
2023-12-11 Chinese
哈药集团股份有限公司董事会审计委员会工作细则(2023年12月）
Governance Information Classification · 95% confidence The document is titled as the "Board Audit Committee Working Rules" of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the structure, responsibilities, and procedures of the Board's Audit Committee, including internal audit functions, audit committee meetings, and interaction with external auditors. It references company governance, audit oversight, and internal control evaluation but does not contain financial statements or financial results. It is a governance-related document outlining internal rules and committee functions rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length (6046 characters) and content confirm it is a detailed governance policy document, not a report publication announcement or regulatory filing.
2023-12-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.